Phase 3 clinical trials continue, with approval decisions expected sometime between late 2026 and early 2027
Prescription medications have undergone extensive clinical trials demonstrating significant weight loss in controlled conditions
Despite this, there is a growing and concerning market for retatrutide and other research peptides sold online, often marketed to bodybuilders or individuals seeking weight loss
The most defensible summary is that tirzepatide is the evidence-complete option available today, and retatrutide is the higher-ceiling candidate whose full value and full risk profile will only be known when its phase 3 program is published, scrutinized, and, if warranted, translated into an approval and a label
Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake
My Protocol: Started at 2mg weekly, increased to 4mg at week 5, reached 8mg by week 12